The thesis

Waters Corporation operates in the Healthcare and Biotech sectors with a 105.7% revenue growth rate and 36.3% gross margin. The analyst consensus is BUY, but the Decifer score is 23, indicating dormancy. The high P/E ratio of 108.2x reflects high expectations. The tension between high growth and high valuation makes the setup interesting.

Why now

The recent revenue growth surge and the macro context of potential market rotation after a Fed hike cycle make this a timely moment to assess Waters Corporation. A 6.8% average gain within a year after a Fed hike cycle begins is historically observed.

What to watch

The next quarter's revenue growth rate and gross margin will indicate whether Waters Corporation can sustain its current performance. The company's guidance and management commentary on the impact of macroeconomic factors will also be crucial.

Key risks

The high valuation (P/E 108.2x) poses a risk if growth slows. Execution risk is also present if the company fails to maintain its 105.7% revenue growth rate. Macro risks, such as European debt concerns affecting the Euro and French stocks, could impact Waters Corporation's European operations.

Theme exposure